Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19

Richardson, Christopher D.

doi:10.1016/s0140-6736(21)02757-4

Cited by 3 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other struggles include its supply and availability issues, and emergence of new variants, which has necessitated the use of heterologous vaccination approach known as mixing vaccines (Rashedi et al 2022 ). Studies by Richardson ( 2022 ) shown protection against COVID-19 by mixing m-RNA, spike adjuvant, and adenoviral vaccines for protection against SARS-CoV-2.…”

Section: Emerging Strategies To Combat Uncertain Covid-19 Diseasementioning

confidence: 99%

Current clinical status of new COVID-19 vaccines and immunotherapy

Nagpal

Kaushik

et al. 2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

COVID-19, caused by SARS-CoV-2, is a positive-strand RNA belonging to Coronaviridae family, along with MERS and SARS . Since its first report in 2019 in Wuhan, China, it has affected over 530 million people and led to 6.3 million deaths worldwide until June 2022. Despite eleven vaccines being used worldwide already, new variants are of concern. Therefore, the governing bodies are re-evaluating the strategies for achieving universal vaccination. Initially, the WHO expected that vaccines showing around 50–80% efficacy would develop in 1–2 years. However, US-FDA announced emergency approval of the two m-RNA vaccines within 11 months of vaccine development, which enabled early vaccination for healthcare workers in many countries. Later, in January 2021, 63 vaccine candidates were under human clinical trials and 172 under preclinical development. Currently, the number of such clinical studies is still increasing. In this review, we have summarized the updates on the clinical status of the COVID-19 and the available treatments. Additionally, COVID-19 had created negative impacts on world’s economy; affected agriculture, industries, and tourism service sectors; and majorly affected low-income countries. The review discusses the clinical outcomes, latest statistics, socio-economic impacts of pandemic and treatment approaches against SARS-CoV-2, and strategies against the new variant of concern. The review will help understand the current status of vaccines and other therapies while also providing insights about upcoming vaccines and therapies for COVID-19 management. Graphical abstract Supplementary Information The online version contains supplementary material available at 10.1007/s11356-022-22661-1.

show abstract

Section: Emerging Strategies To Combat Uncertain Covid-19 Diseasementioning

confidence: 99%

Current clinical status of new COVID-19 vaccines and immunotherapy

Nagpal

Kaushik

et al. 2022

Environ Sci Pollut Res

View full text Add to dashboard Cite

show abstract

Chemical engineering of electrospun nanofibrous‐based three‐layered nonwoven polymeric protective mask for enhanced performance

Chen

Soni

Huyen

et al. 2023

J of Applied Polymer Sci

View full text Add to dashboard Cite

show abstract

Biomimetic Nanovaccines: A Novel Approach in Immunization

Khojini,

Babaei,

Shakarami

et al. 2023

CPD

View full text Add to dashboard Cite

As the World Health Organization (WHO) declared, vaccines prevent an average of 2-3 million deaths yearly from diseases. However, effective prophylactic and therapeutic vaccines have yet to be developed for eradicating the deadliest diseases, viz., types of cancer, malaria, human immunodeficiency virus (HIV), and most serious microbial infections. Furthermore, scores of the existing vaccines have disadvantages, such as failure to completely stimulate the immune system, in vivo instability, high toxicity, need for the cold chain, and multiple administrations. Thus, good vaccine candidates need to be designed to elicit adaptive immune responses. In this line, the integration of sciences along with the use of various technologies has led to the emergence of a new field in vaccine production called biomimetic nanovaccines (BNVs). Given that, nanotechnology can significantly contribute to the design of such vaccines, providing them with enhanced specificity and potency. Nanoparticles (NPs) and biomimetic NPs (BNPs) are now exploited as the main carriers for drug delivery systems, especially BNPs, whose biological mimicry makes them escape the immune system and transport drugs to the desired target. The drug accordingly seeks to camouflage itself with the help of NPs and the membranes taken from cells in the human body, including red blood cells (RBCs), white blood cells (WBCs), platelets, and cancer cells, for more effective and ideal delivery. As BNPs have recently become the center of attention in vaccine design, this review deliberates on the advances in BNVs.

show abstract

Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19

Cited by 3 publications

References 12 publications

Current clinical status of new COVID-19 vaccines and immunotherapy

Current clinical status of new COVID-19 vaccines and immunotherapy

Chemical engineering of electrospun nanofibrous‐based three‐layered nonwoven polymeric protective mask for enhanced performance

Biomimetic Nanovaccines: A Novel Approach in Immunization

Contact Info

Product

Resources

About